The dynamic interplay between ER signaling and important cell cycle regulators such as Cyclin-dependent kinase 4 and 6 (CDK4/6) has enabled the development of a new class of anticancer agents called CDK4/CDK6 inhibitors, which are extensively used in the treatment of metastasized ER-positive BC [39]. Here, ESR1 is linked to breast cancer.